Investment Rating - The report maintains a "Buy" rating for China Resources Sanjiu (000999.SZ) [3][7]. Core Views - The company's "one body, two wings" strategy has shown effectiveness, driving growth through innovation and acquisitions [7]. - The revenue for 2025 is projected at 31.603 billion yuan, with a year-on-year growth of 14.43%, while the net profit attributable to shareholders is expected to be 3.421 billion yuan, reflecting a year-on-year increase of 1.58% [7]. - The report anticipates revenue growth for 2026 to 2028 at 10.6%, 9.4%, and 8.8% respectively, with net profit growth rates of 10.8%, 13.3%, and 11.5% [7]. Financial Forecasts and Indicators - **Revenue Forecast**: - 2025: 31,603 million yuan - 2026: 34,937 million yuan - 2027: 38,208 million yuan - 2028: 41,582 million yuan - Growth Rates: 14.4% (2025), 10.6% (2026), 9.4% (2027), 8.8% (2028) [3][8] - **Net Profit Forecast**: - 2025: 3,421 million yuan - 2026: 3,792 million yuan - 2027: 4,296 million yuan - 2028: 4,791 million yuan - Growth Rates: 1.6% (2025), 10.8% (2026), 13.3% (2027), 11.5% (2028) [3][8] - **Earnings Per Share (EPS)**: - 2025: 2.06 yuan - 2026: 2.28 yuan - 2027: 2.58 yuan - 2028: 2.88 yuan [3][8] - **Valuation Ratios**: - Price-to-Earnings (P/E): 14 (2025), 12 (2026), 11 (2027), 10 (2028) - Price-to-Book (P/B): 2.1 (2025), 2.0 (2026), 1.8 (2027), 1.6 (2028) [3][8] Business Segments - **Consumer Health Care (CHC)**: - Revenue: 151.11 billion yuan, accounting for 47.81% of total revenue, with a gross margin of 61.67% [7]. - **Prescription Drugs**: - Revenue: 120.94 billion yuan, accounting for 38.27% of total revenue, with a gross margin of 58.81% [7]. Dividend Policy - The company distributed a total cash dividend of 1.731 billion yuan in 2025, with a payout ratio of 50.59% and a dividend yield of 3.65% [7].

Core Insights - The Shanghai Stock Exchange International Investor Conference emphasizes the theme "Value Leading, Open Empowerment - New Opportunities for International Capital Investment and M&A" [1] - The conference serves as a platform for foreign investment institutions to communicate with domestic regulatory bodies, exchanges, listed companies, and financial institutions [1] Group 1: Investment Landscape - Temasek's investment strategy in China has evolved over 20 years, aligning with China's economic transformation and capital market development [2] - Temasek's focus areas include digitalization, sustainable living, new consumption, and longevity, which are crucial for China's future economic direction [2][3] - The firm has diversified its investment strategies across public markets, private equity, special transactions, funds, and strategic partnerships [2] Group 2: Economic Resilience - China's economy demonstrates strong resilience due to coordinated fiscal and monetary policies, transitioning from "stabilizing growth" to "promoting innovation" [2][3] - The government is promoting a unified market and guiding resources towards high-value sectors, while also implementing consumption stimulation and investment incentives [3] Group 3: M&A Market Dynamics - The current Chinese investment and M&A market is characterized by a "dual-driven" phenomenon, with mature industries entering a merger and acquisition phase [4] - Mergers and acquisitions are seen as essential for optimizing resource allocation and adjusting industrial structures, enhancing market concentration [4][5] - China's unique supply-demand ecosystem fosters rapid growth of world-class companies, supported by a large, digitalized market and efficient supply chains [4][5] Group 4: Future Outlook - Temasek aims to build a resilient and forward-looking investment portfolio in China, focusing on long-term, patient, and value-driven capital [5] - The firm anticipates continued collaboration with regulatory bodies and partners to leverage capital as a driver of innovation and value creation [5]